Inactive Instrument

Luye Pharma Group Ltd Stock Singapore S.E.

Equities

LUYE

BMG5722Z1014

Pharmaceuticals

Financials

Sales 2023 6.14B 848M 1.15B Sales 2024 * 7B 966M 1.31B Capitalization 9.22B 1.27B 1.73B
Net income 2023 533M 73.56M 100M Net income 2024 * 669M 92.33M 126M EV / Sales 2023 2.08 x
Net Debt 2023 * 3.67B 506M 689M Net Debt 2024 * 2.95B 407M 553M EV / Sales 2024 * 1.74 x
P/E ratio 2023
23.7 x
P/E ratio 2024 *
15.3 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 54.94%
More Fundamentals * Assessed data
Dynamic Chart
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610 CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3% MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List MT
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval MT
Pharma Mar Partner Wins Marketing Approval for Lung Cancer Drug in Hong Kong MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong CI
Luye Pharma Group Ltd. Announces Board Changes CI
Chinese Regulator Green Lights Luye Pharma’s Small Cell Lung Cancer Drug MT
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao MT
China Gives Marketing Green Light to Luya Pharma's Patch Treatment for Alzheimer's Disease MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China CI
More news
Managers TitleAgeSince
Chief Executive Officer 59 03-07-01
President 58 94-06-07
Corporate Officer/Principal 60 94-06-07
Members of the board TitleAgeSince
Director/Board Member 65 94-06-07
President 58 94-06-07
Chief Executive Officer 59 03-07-01
More insiders
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
More about the company